

# **OSTEOPOROSIS**

# THIRD EDITION • TWO-VOLUME SET

Edited by

#### **Robert Marcus**

Professor Emeritus, Stanford University, Palo Alto, California, U.S.A.

#### **David Feldman**

Stanford University School of Medicine, Palo Alto, California, U.S.A.

#### **Dorothy A. Nelson**

Wayne State University, Detroit, MI, U.S.A.


#### Clifford J. Rosen

St. Joseph Hospital, Bangor, Maine, U.S.A.

Now in its third edition, **Osteoporosis** is the most comprehensive, authoritative reference on this disease. Written by renowned experts in the field, this two-volume reference is a must-have for academic and medical libraries and physicians. Worldwide, 200 million women between 60-80 years of age suffer from osteoporosis and have a lifetime risk of fracture between 30 and 40 percent continuing to make osteoporosis a hot topic in medicine. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in a field where direct care costs for osteoporitic fractures in the U.S. reach up to \$18 billion each year. Academic and medical libraries, as well as professionals in bone biology, endocrinology, osteology, neuroendocrinology and drug companies developing osteoporosis medications will find all of their information needs met in this classic reference.

#### NEW TO THIS EDITION:

- ♦ Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics comprising a tremendous wealth of knowledge in a single source not found elsewhere
- ◆ Examines essential updates on estrogen prevention and treatment and the recent results from the Women's Health Initiative
- ◆ Recognizes the critical importance of the Wnt signaling pathway for bone health
- ◆ Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone
- ◆ Discusses the controversial topics of screening and clinical trial design for drug registration
- ◆ Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone



September 2007, Hardback c. 1900 pp. ISBN: 9780123705440

INTRODUCTORY PRINT PRICE\*: \$320.00 / €270.00 / £185.00

List Print Price: \$400.00 / €335.00 / £230.00

\*Introductory prices are valid for three months after publication.

books.elsevier.com/osteo




Also available online via ScienceDirect™!

See inside flap for details!



ELSEVIER
MARKETING DEPARTMENT DM89535
525 B Street, Suite 1900
San Diego, CA 92101-4495, USA

Presorted Standard
U.S. Postage
PAID
Elsevier



ALSO AVAILABLE ONLINE VIA



www.info.sciencedirect.com

## **OSTEOPOROSIS**

THIRD EDITION, TWO-VOLUME SET November 2007, Hardback c. 1900 pp, ISBN: 9780123705440

# INTRODUCTORY PRINT PRICE\*: \$320.00 / €270.00 / £185.00

List Print Price: \$400.00 / €335.00 / £230.00 Prices are in US Dollar, Euro, and British Pound Sterling and are subject to change without notice.

Introductory price valid for three months after publication date

### Order from your favorite bookseller or directly from:

In the Americas, Asia & Australia: **ELSEVIER** 

Order Fulfillment Department 11830 Westline Industrial Drive St. Louis, MO 63146-9938, USA

Tel: 1 800 545 2522 Fax: 1 800 535 9935

Name (Please Print)

E-mail: usbkinfo@elsevier.com

In Europe, Middle East & Africa: **ELSEVIER** 

Books Customer Service Linacre House

Jordan Hill, Oxford, OX2 8DP, UK Tel: +44 1865 474110

Tel: +44 1865 474110 Fax: +44 1865 474111

E-mail: eurobkinfo@elsevier.com

FAX OR MAIL THIS FORM • DM89535					
ISBN: 9780123705440, Osteoporosis, Third Edition, 2-Volume Set					
<u>Qty</u>	<u>Prices</u>	<u>Amount</u>			
	Introductory Print Price: \$320.00/€270.00/£185.00 List Print Price: \$400.00/€335.00/£230.00	0 \$/€/£			
	Shipping*	\$/€/£			
	Local Sales Tax*	\$/€/£			
	Total	\$/€/£			
□ Places find my check anclosed*					

Please	find r	ny c	heck	enclo	sed*
Plasca	charo	, m	v cro	dit car	d*

☐ Bill my company (purchase order attached)\*

☐ Bill me directly

\*Local sales tax, VAT or GST taxes and shipping will be added where applicable. For shipping and sales tax rates based on your mailing address, please contact us.

Tel. ()		Fax ()	
Address			
City	State	_Zip/Postcode	Country
E-mail			
DISCOVER Mas(ercard) VISA			
Charge Card#			Exp. (Mo/Yr)


☐ Please remove my details from your mailing list.

Signature



# OSTEOPOROSIS

THIRD EDITION • TWO-VOLUME SET



Edited by

Robert Marcus
David Feldman
Dorothy A. Nelson
Clifford J. Rosen

books.elsevier.com/osteo

## TABLE OF CONTENTS

#### Introduction

The Bone Organ System: Form and Function Elise F. Morgan, George L. Barnes, and Thomas A. Einhorn

The Nature of Osteoporosis Robert Marcus and Mary Bouxsein

The Economics of Osteoporosis Anna N.A. Tosteson and David J. Vanness

Reflections on Osteoporosis B. E. Christopher Nordir

Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis Michael Parfitt

#### **Basic Science/Bone Biology**

Osteoblast Biology Jane B. Lian and Gary S. Stein

**Osteoclast Biology** Harry C. Blair, Scott Simonet, David L. Lacey, and Mone Zaidi

Osteocytes Lynda F. Bonewald

The Regulatory Role of Matrix Proteins in Mineralization of Bone

Wei Zhu, Pamela Gehron Robey and Adele L. Boskey

**Development of the Skeleton** Sylvain Provot, Ernestina Schipani, Joy Wu and Henry Kronenberg

Mouse Genetics as a Tool to Study Bone Development and Physiology Clifford J. Rosen and Wesley G. Beamer

Parathyroid Hormone and Parathyroid Hormone-Related Protein

Robert A. Nissenson

Vitamin D: Biology, Action, and Clinical Implications David Feldman, Peter J. Malloy, Aruna V. Krishnan and Eva Balint

**Regulation of Bone Cell Function by Estrogens**Barry S. Komm, Boris Cheskis and Peter V.N. Bodine

Androgens and Skeletal Biology: Basic Mechanisms Kristine M. Wiren

**Phosphatonins** 

Peter J. Tebben, Theresa J. Berndt, and Rajiv Kumar

Wnt Signaling in Bone Mark L. Johnson nd Robert R. Recker

**Cytokines and Bone Remodeling** Gregory R. Mundy, Babatunde Oyajobi, Gloria Gutierrez, Julie Sterling, Susan Padalecki, Florent Elefteriou, Ming Zhao

Skeletal Growth Factors

Intercellular Communication During Bone Remodeling T. John Martin and Gideon A. Rodan

#### **Structural and Biomechanics**

Skeletal Development: Mechanical Consequences of Growth, Aging and Disease

Marjolein C.H. van der Meulen and Dennis R. Carter and Gary S. Beaupré

**Inhibition of Osteoporosis by Biophysical Intervention** Clinton T. Rubin, Stefan Judex, Janet Rubin and Yi-Xian Qin

**Biomechanics of Age-Related Fractures** Mary L. Bouxsein

**Bone Quality** 

J. Christopher Fritton and Mitchell B. Schaffler

#### **Epidemiology & Risk Factors**

**Epidemiologic Methods in Studies of Osteoporosis** MaryFran Sowers and Carrie A. Karvonen-Gutierrez

Race, Ethnicity and Osteoporosis Dorothy A. Nelson, John M. Pettifor and Shane A. Norris

The Study of Osteoporotic Fractures (SOF): Major **Findings and Contributions** 

Jane A. Cauley, Kristine E. Ensrud, Teresa A. Hillier, Marc Hochberg, Katie L. Stone, Steven R. Cummings

Bone Mineral Acquisition in Utero and During Infancy and Childhood

Jon Burnham and Mary B. Leonard

**Bone Acquisition in Adolescence** Moira A. Petit, Heather M. Macdonald, Heather A. McKay and Tom Lloyd

Genetic Determinants of Osteoporosis

André G. Uitterlinden, Fernando Rivadeneira Hans P.T.M. van Leeuwen, Joyce B.J. van Meurs, Huibert A.P. Pols

**Nutrition and Risk for Osteoporosis** Robert P. Heaney

Physical Activity in Prevention of Osteoporosis and **Associated Fractures** 

Kirsti Uusi-Rasi, Pekka Kannus, Harri Sievänen

Premenopausal Reproductive and Hormonal Characteristics and the Risk for Osteoporosis

Non-Skeletal Risk Factors for Osteoporosis and **Fractures** 

Falls as Risk Factors for Fracture Sarah D. Berry and Douglas P. Kiel

Assessment of Fracture Risk

Nguyen Dinh Nguyen and Tuan V. Nguyen

**Outcomes of Osteoporotic Fractures** Gail A. Greendale and Elizabeth Barrett-Connor

#### **Pathophysiology**

Local and Systemic Factors in the Pathogenesis of Osteoporosis Lawrence G. Raisz

**Animal Models for Osteoporosis** Urszula T. Iwaniec and Russell T. Turner

Estrogen, Bone Homeostasis and Osteoporosis B. Lawrence Riggs, Sundeep Khosla, and L. Joseph Melton III

Postmenopausal Osteoporosis: How the Hormonal Changes of Menopause Cause Bone Loss Roberto Pacifici

Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization Eric Orwoll and Robert Klein

Osteoporosis in Childhood and Adolescence Leanne Ward and Laura K. Bachrach

**Glucocorticoid-Induced Osteoporosis** Robert A. Adler, Jeffrey Curtis, Robert S. Weinstein and Kenneth G. Saag

Adult Scoliosis, Degenerative Disease, and BMD:

a Sub-Segmental Analytic Approach Alan L. Burshell and Eric A. Nauman Mechanisms of Immobilization-induced Bone Loss

**Leptin-Dependent Regulation of Bone Mass** Gerard Karse

Thyroid Hormone and the Skeleton

Osteoporosis in Gastrointestinal, Pancreatic, and **Hepatic Disease** Daniel Bikle

The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis John P. Bilézikian, Lorraine Á. Fitzpatrick, and Shonni J. Silverberg

Osteogenesis Imperfecta and Other Defects of Bone **Development as Occasional Causes of Adult** Osteoporosis

Osteoporosis Associated with Illnesses and Medications Hyesoo Lowe and Elizabeth Shane

**Transplantation Osteoporosis** Sol Epstein

Osteoporosis Associated with Cancer Therapy Ailleen Heras-Herzig, Wende M. Kozlow, Sue A. Brown and Theresa A. Guise

Osteoporosis Associated with Pregnancy Rachel B. Wagman and Robert Marcus

Osteoporosis Associated with Rheumatologic Disease Steven Goldring

Oral Bone Loss and Systemic Osteopenia: Potential Treatment and Risks

Marjorie K. Jeffcoat

Localized Osteoporosis D.J. Schurman, W.J. Maloney, and R.L. Smith

#### **Evaluation and Management**

Evaluation of the Patient with Osteoporosis or at Risk for Osteoporosis

Rekha Nugaram, Aysegul Atmaca, and Michael Kleerekoper

Who Should be Screened: Who Should be Treated? Michael R. McClung

Radiology of Osteoporosis Michael Jergas and Harry K. Genant

Clinical Use of Bone Densitometry Kenneth G. Faulkner and Paul D. Miller

**Biochemical Markers of Bone Turnover in Osteoporosis** Pawel Szulc and Pierre D. Delmas

The Conundrum of Compliance and Persistence with Oral Bisphosphonates for Postmenopausal Osteoporosis Deborah T. Gold and Samantha Solimeo

An Orthopedic Perspective of Osteoporosis Charles Reitman, Kenneth Mathis and Michael H. Heggeness

**Lessons from Bone Histomorphometry on the** Mechanism of Action of Osteoporosis Drugs Hua Zhou and David W. Dempster

#### **Pharmacology and Therapeutics**

Design Considerations for Clinical Investigations of Osteoporosis Robert P. Heaney

Regulatory Considerations for the Design and Conduct of Osteoporosis Registration Trials

Bruce H. Mitlal **Evidence-Based Osteoporosis Care** Kurt A. Kennel, Brian A. Swiglo, and Victor M. Montori

The Role of Calcium in the Treatment of Osteoporosis

Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis Roger Bouillon and Ian R. Reid

**Estrogen Therapy: Prevention and Treatment of** Osteoporosis / Joan A. McGowan and Marcia L. Stefanick

Estrogen Analogues: Selective Estrogen Receptor Modulators (SERMs) and Phytoestrogens Richard Prince, Douglas B. Muchmore and Ethel S. Siris

Bisphosphonates: Pharmacology and Use in the **Treatment of Osteoporosis** Paul D. Miller

Calcitonin in Osteoporosis Roberto Civitelli


Strontium Therapy for Osteoporosis

Androgens Peter J. Snyder

**Treatment with PTH Peptides** Felicia Cosman and Robert Lindsay

Growth Hormone and Insulin-like Growth Factors: Potential Applications and Limitations in the Management of Osteoporosis Clifford J. Rosen and Tim Niu

**New Approaches to Osteoporosis Therapeutics** Rivka Dresner-Pollak, S. Aubrey Stoch and Michael Rosenblatt



# **OSTEOPOR**(

THIRD EDITION • TWO-VOI

## Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis

A. M. PARFITT

II. Skeletal Heterogeneity

III. The Purposes of Bone Remodeling IV. Implications for Understanding Osteop

#### I. INTRODUCTION

The cells of bone influence its six sture by means of four processes: growth, repair, modeling, and remodfour processes: growth, repair, modeling, and remodeling, the last being the basis of bone tissue to gover in the adult skeleton. The purposes of growth and continuous Modeling serves to adapt bones to change in mechanical loading [1], and remodeling serves to thicken trabeculae in the growing skeleton [2], processes that are most effective during adolescence [3]. But why does a tissue that can survive for thousands of years after death need to be maintained by periodic replacement during life? Most of those interested in bone, whether as physicians, as clinical investigators, replacement during lite? Most of those interested in bone, whether as physicians, as clinical investigators, or as basic scientists, show remarkably little interest in this fundamental question. Many articles and book chapters discuss the regulation of bone remodeling, but regulation, at least in the physiologic sense, implies a target [4]. The target value of any regulatory process in biology has been optimized by natural selection. Mechanisms have evolved which ensure that deviations from the target are detected and that corrective meas ures to restore the target value are carried out. In this sense, body temperature, extracellular fluid osmolality, tissue oxygen tension, and countless other physi-ologic quantities are regulated, but the mechanisms of regulation could not be determined until the existor regulation could not be destinated and its precise ence of the target had been recognized and its precise nature defined. Is there a target for bone remodeling or for some characteristic of bone that is influenced by

The piecemeal, quantal nature of bone remodeling is well known. The process is carried out by tempo-rary anatomic structures known as basic multicellular units, or BMUs [5-8], which excavate and replace tunnels through cortical bone (osteonal remodeling) or trenches across the surface of cancellous bone

VITAMIN D, 2nd Edition Fel dman, Pike, And Gl or ieux

(hemiosteonal remodeling). Each BMU includes two (nemiosteonal remodering). Each BMU includes two teams of executive cells (osteoclasts and osteoblasts), supported by blood vessels, nerves, and loose connective tissue. The life span of the BMU is measured in months, but the life span of osteoblasts while they are making bone is measured in weeks, and the life span of osteoblast model is measured in days. During propers. osteoclast nuclei is measured in days. During pr osteoclast nuclei is measured in days. Daring progression of the BMU through or across the surface of bone, the stail and temporal relationships between its com-

the setial and temporal relationships between its com-ponents as maintained by the continued growth of the central capilla v in cortical bone [9], and extension of the remodeling compartment in cancellous bone [10], together with recruitment of new cells [9–11]. These cells, like the formed elements of the blood, originate from stem cells in the bone mayow [12] except that in the peripheral expleton osteoblasts are derived fror

**Bold internal headings direct reader** lived cells, more impor to sections within each article tion: although

also to bone ceus [12].

Each type of blood cell is normally produced basal rate that is sufficient for ordinary purposes be can be increased when needed [13]. For each cell the circumstances under which demand is inc are well known, and are related to the func the particular cell, although the cell types dif the particular cert, animogn the expert some respect to the time scale of this response, its sp the relative importance of reactive and an homeostasis [14], and the extent to which t' mechanisms have been elucidated. The imp these relationships between supply and de between demand and function, applies a cells. For osteoblasts in the adult nongrow the demand is created by bone resorpti function of osteoblasts is to replace the by osteoclasts. However, the circumstar

a demand for osteoclasts are much less well defined, since these circumstances are dictated by the purposes of bone remodeling. Indeed, the questions "What are the purposes of bone remodeling and how are they achieved," are essentially equivalent to the questions "Where and when are osteoclasts needed, and how is this need recognized and satisfied," The answers to these questions are different in different types of bone these questions are different in different types of bone and in different regions of the skeleton.

## II. SKELETAL HETEROGENEITY

### Structure and Function

The structural differences between cortical bone, in which porosity and surface-to-volume ratio are low, and cancellous bone, in which these geometric quantiand cancellous bone, in which these geometric quanti-ties are high [15], are now widely recognized. All inter-mediate values for these quantities can occur, but they are infrequent, implying that transitional structures tend to be temporary and short-lived [16]. Less often noted are the differences between the axial and amentend to be temporary and snort-fived [16]. Less often noted are the differences between the axial and appendicular the skeleton (Table 5-1); the

ly as appendicular, behaves axial skeleton, so that it rticle ast central with peripheral is important because the dif-

between the central and peripheral components. The primary function is load-bearing—to support posture, permit movement (including locomotion), and provide protection for the soft tissues. Subsidiary functions are to participate in mineral homeostasis and to provide a favorable microenvironment for hematopoiesis. For convenience the former functions will be referred to as "mechanical" and the latter as "metabolic" [13]. It is commonly believed that the mechanical functions are carried out mainly by cortical bone and the metabolic functions mainly by cancellous bone, regardless of their central or peripheral locations. In fact, the

TABLE 5-1 Subdivisions of the Sk

Feature	on the Skeleton		
Main bone tissue	Central	Peripheral Cortical Muscle	
Main soft tissue Main joint type Cortices	Cancellous Viscera Various Thin		
Marrow Turnover	Heman metic	Thick Fatty Low	

shap

the h


perip

Informative and instructive tables and figures supplement and support the text

> In-depth captions provide additional information

books.elsevier.com/osteo





A. M. PARFITT

unctions of the peripheral skeleton, cancellous as well s cortical, are mainly mechanical, whereas the central scleton, cortical as well as cancellous, in addition to celeton, cortical as well as cancellous, in addition to mechanical function, participates to a much greater tent in the metabolic functions of bone. This revision functional attribution is most striking for peripheral necllous bone, such as in the metaphyses of the long necllous bone, such as in the metaphyses of the long necllous bone, such as in the metaphyses of the long necllous bone, and the point surfaces to diaphyseal cancellous bone. Indeed, the metaphyses are flared in ep receisely to make such load transmission possibility. Similar functional and architectural considerae precisely to make such load transmission pos-ingly to the cancellous bone in the small bones of ands and feet (Figure 5-1b). As will subsequently scussed in detail, there is no evidence that such neeral cancellous bone participates to a signifi-stream in the metabolic functions of the skeleton, er related to mineral homeostasis or to hemat is.





(a) Examples of trabecular orientation in ellous bone in the appendicular skelton. The sess trajectories facilitates transmission of loads iaphyseal cortical bone. (b) Examples of on in the small bones of the feet. The alignment is facilitates mission of loads during the point of the property of the property of the skel joint and thence to diaphyseal cortical ddiffed from [17].

ACKNOWLEDGMENTS

Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P60-AR048094) and the National Institute on Aging (R01-AG12262).

### References

value. To date, however, neem to those conducting cause individuals discon-ed to do so early, incurring

best-case" theoretical eco-studies showing relatively

dherence suggest that such imistic [60]. As additional

with different adherence important to integrate such

economic and quality of t determinants of the cost-intervention. Early stud-

gical agents to adversely idered. In this context, a

Y impact of side effects

H DIRECTIONS idence that osteoporosis roblem in elderly popu-tudies have established

priority, cost-effective-

Cross references lead reader to explore articles of related interest

- ed to do so early, incurring In some jurisdictions, such e decision makers consider taking health policy deci-pharmaceuticals, an analy-ull continuation is required, best-case" theoretical eco-
- References

  1. Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General. In U. S. Department of sis: A report of the Surgeon General. In U. S. Department of L. J. Melton, 3rd. Hig fees, Rockville, MD (2004).

  2. L. J. Melton, 3rd. Hig fees, Rockville, MD (2004).

  3. A. Rodell, P. N. Sartures: A worldwise problem today and tomorow. Bone. 14(Suppl.) S. 13-8 (1993).

  3. G. Jones, P. J. Kelly, and J. A. Eisman of Surgeon, H. Lapsley. Genes of Osteoporoic firstures in elderly men and well. A suide to current and M. Meiners. Cost-of-illness methodology: A suide to current meltod. A suide to current meltod. Part of the Management of the Medical States of Cost. A suide to current methods. Pharmacoeconomics. A sudde: A review of current methods. Pharmacoeconomics. A sudde: A review of current methods. Pharmacoeconomics. S. E. Gabriel, A. N. Tosteson, C. L. Leibson, C. S. Crowson, medical code C. S. Hammond, and L. J. Melton, 3nd. Direct Int. 13, 323-330 (2002).

  3. T. Mittendorf, S. Merkesdal, J. L. Huelsemann, J. M. von standardized cost categories within economic evaluations of standardized cost categories within economic evaluations (2003).

  3. Ray, J. Chan, M. Thamer, and L. J. Melton. Medical expenditures for the treatment of osteoporotic fractures in the United
- intervention, Early stud-ppausal hormone therapy e menopausal symptoms of treatment may be out-ffects if associated with year [61, 62]. Thus, the peical agents to adversely
  - (2003).

    8. N. Ray, J. Chan, M. Thamer, and L. I. Melton. Medical expensions for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res., 12, 24–35 (1997).

    9. T. Holbrook, K. Joseph Miner Res., 12, 24–35 (1997).

    9. T. Holbrook, T. Bone Miner Res., 12, 24–35 (1997).

    9. Frequency of Occurrence, Impact Gost of Muscaloskeletal Conditions in the United States, Pp. 1–187. American Academy Of March States, Pp. 1–187. American Academy Durchen of osteoporosis in California, 1998. Osteoporos Int., 13, 493–400.
- Impact of side effects it following a BMD test er is reassuring because is identified for women mate [63].
- burden of osteoporosis in California, 1998. Osteoporos Int. 13.

  493-500 (2002).

  10. A Praemer, S. Fumer, and D. Rice. Musculoskeletal Conditions in the United States, pp. 1-199. American Academy of Orthopaedic Conditions in the United States, pp. 1-199. American Academy of Orthopaedic Conditions, and the United States. A Praemer, S. Furner, and D. Rice. Musculoskeletal Conditions in the United States. A American Academy of Orthopaedic Conditions of the United States. American Academy of Orthopaedic Conditions. P. S. Arno, C. Levine, and M. M. Memmott. The economic Pass (1999).

  13. P. S. Arno, C. Levine, and M. M. Memmott. The economic Value of informal caregiving. Health Aff (Millwood). IS. 188 (1999).

  14. R. Burge, B. Dawson-Hughes, D. H. Solomon, J. B. Wong, A. King, and A. N. Tosteson. Incidence and economic burden 2025. J Done Miner Ref Croures in the United States, 2005—10. Vanness, and A. Tosteson. Estimating the opportunity costs of 14. 4–16 (2005).

  15. D. Vanness, and A. Tosteson. Estimating the opportunity costs of 14. 4–16 (2005).

  16. E. Chrischilles, T. Shireman, and R. Wallace. Costs and health P. L. S. Orsini, M. D. Rousculp, S. R. Gong, and S. Wang, Health of osteoporosis-related fractures. Bone, 18, 377–386 (1994).

  16. Carrisin, M. D. Rousculp, S. R. Gong, and S. Wang, Health of osteoporosis-related fractures. Osteoporosis in 16, 359–371 (2005).

  18. S. Phillips, N. Fox, J. Jacobs, and W. Wright. The direct medical cost of osteoporosis for American. priority, cost-effective d efficient approaches to prevent the economic costs effective approaches to osteoporosis, it is imperative that cost-treatment be identified and successfully implemented. To accomplish this, additional data on the longitudinal and quality of life are required.
  - (2005).
     (18. S. Phillips, N. Fox, J. Jacobs, and W. Wright. The direct medical cost of osteoporosis for American women aged 45 and older. Bone. 9, 271–279 (1988).
     (19. A. C. Sasser, M. D. Rousculp, H. G. Birnbaum, E. F. Oster, breast cancer, and D. Mallet. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmeno-



In addition to the reference works, handbooks and book series already available, ScienceDirect will launch approximately 4,000 books online in 2007, including *Osteoporosis!* 

#### BENEFITS OF SCIENCEDIRECT

- Acquiring books on ScienceDirect enables librarians to best serve their user communities by providing simultaneous and remote user access, maximizing user productivity
- Helps researchers find and manage information easily and allows them to set up alerts to be updated on the latest developments
- Includes titles from high quality imprints such as Academic Press and Pergamon
- Flexible business models are available
- Pick and choose any book title or according to ScienceDirect subject collections



makes sense.

For additional information, including pricing options, please visit

www.info.sciencedirect.com/books